Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Caroline Marre
Observed name:
C. Marre
Institution:
Creativ-Ceutical (France)
Observed institution:
Creativ-Ceutical (France)
OpenAlex ID:
A5089116238
Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review
2019
·
Rupert Bauersachs
, Uwe Zeymer
, et al.
·
Cardiovascular Therapeutics
·
540
PDF
Synthesis and Comparison of the Meta-Analyses Evaluating the Efficacy of Memantine in Moderate to Severe Stages of Alzheimer’s Disease
2013
·
Benoît Rive
, Serge Gauthier
, et al.
·
CNS Drugs
·
21
PDF
Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes
2014
·
Laura Sawyer
, Jean-Michel Azorin
, et al.
·
Journal of Medical Economics
·
15
PDF
Pbi59 the Reimbursement Status of Advanced Therapy Medicinal Products in Europe
2019
·
E. Hanna
, C. Marre
, et al.
·
Value in Health
·
4
PDF
Php307 - Reimbursement of Advanced Therapy Medicinal Products in Europe
2018
·
E. Hanna
, C. Marre
, et al.
·
Value in Health
·
2
PDF
Php125 - Cohort Temporary Authorisation for Use in France, French Experience of Early-entry Program 2014-2018
2018
·
A. Weber
, C. Dussart
, et al.
·
Value in Health
·
2
PDF
2584 – Comparison of Metabolic Syndrome Incidence Among Schizophrenia Patients Treated with Asenapine Versus Olanzapine
2013
·
M. De Hert
, A. Guiraud-Diawara
, et al.
·
European Psychiatry
·
2
Pro9 a Systematic Review of the Clinical Burden of Idiopathic Multicentric Castleman's Disease
2019
·
B. Smela-Lipińska
, C. Marre
, et al.
·
Value in Health
·
1
PDF
Pro144 Health-related Quality of Life and Patient Reported Outcomes Measures in Idiopathic Multicentric Castleman's Disease: a Systematic Review
2019
·
B. Smela-Lipińska
, C. Marre
, et al.
·
Value in Health
·
1
PDF
Pdg58 the Impact of Economic Regulation on Expansive Drug List in France Between 2008 and 2018
2019
·
C. Blein
, C. Marre
, et al.
·
Value in Health
PDF
Pns165 the Use of Managed Entry Agreements for Advanced Therapies in Eu5
2019
·
E. Hanna
, C. Marre
, et al.
·
Value in Health
PDF
Pdg59 the Impact of Temporary Authorization Use (atu) Dossier in France Since the Creation of Ffip (pharmaceutical Innovation Financing Fund) in 2017
2019
·
C. Blein
, C. Marre
, et al.
·
Value in Health
PDF
Pro42 the Clinical, Humanistic and Economic Burden of Bronchiolitis Obliterans Syndrome in Europe
2019
·
N.R. Henig
, C. François
, et al.
·
Value in Health
PDF
Pmu63 French Health Technology Assessment of Drugs Approved Under Exceptional Circumstances
2019
·
T. Qiu
, E. Hanna
, et al.
·
Value in Health
PDF
Php124 - Intransparent Exceptional Funding in France Ensuring Continuity of Patient Access to Innovative Treatment
2018
·
A. Weber
, C. Marre
, et al.
·
Value in Health
Php348 - Regenerative Medicine Advanced Therapy: a Budget Impact Analysis
2018
·
E. Hanna
, C. Marre
, et al.
·
Value in Health
Php119 - Disruption in Patient Access to Innovative Therapy in France After Interruption of Nominative Temporary Authorisation for Use
2018
·
A. Weber
, C. Marre
, et al.
·
Value in Health
PDF
Php118 - Impact of Cohort Temporary Authorisation for Use on Price in France
2018
·
C. Dussart
, A. Weber
, et al.
·
Value in Health
PDF
P3‐411: The Role of Dependence in Alzheimer's Disease Dementia: A Systematic Literature Review
2016
·
Caroline Marre
, Kimberly Riggs
, et al.
·
Alzheimer s & Dementia
Cost-Effectiveness of Asenapine in the Treatment of Bipolar Disorder I Patients with Mixed Episodes
2013
·
J.M. Azorin
, L. Sawyer
, et al.
·
Value in Health
PDF
PMH20 Metabolic Consequences and Cost-Effectiveness of Asenapine in the Treatment of Bipolar Disorder
2012
·
C. Selya-Hammer
, A. Gauthier
, et al.
·
Value in Health
PDF
Show more works
View as search
Works count:
21
Citation count:
587
H-index:
4
I10-index:
3
Year
Topic
Type